Literature DB >> 15585302

Immune-based therapies for prostate cancer.

Douglas G McNeel1, Miroslav Malkovsky.   

Abstract

Prostate cancer is a leading cause of cancer morbidity and mortality in the United States. Animal and clinical studies performed four decades ago suggested that immunological approaches might be useful for the treatment of prostate cancer. The wealth of information that has been learned over the last two decades has suggested many new directions to the immune-based therapy of prostate cancer, including passive and active immunotherapy approaches. The findings from current trials, and the likely combination of current immunotherapy approaches with conventional therapies, portends a hopeful future for the treatment of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15585302     DOI: 10.1016/j.imlet.2004.06.009

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  9 in total

1.  Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

Authors:  Francesco Dieli; David Vermijlen; Fabio Fulfaro; Nadia Caccamo; Serena Meraviglia; Giuseppe Cicero; Andrew Roberts; Simona Buccheri; Matilde D'Asaro; Nicola Gebbia; Alfredo Salerno; Matthias Eberl; Adrian C Hayday
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

2.  Assessment of tumor-infiltrating TCRVγ9Vδ2 γδ lymphocyte abundance by deconvolution of human cancers microarrays.

Authors:  Marie Tosolini; Frédéric Pont; Mary Poupot; François Vergez; Marie-Laure Nicolau-Travers; David Vermijlen; Jean-Emmanuel Sarry; Francesco Dieli; Jean-Jacques Fournié
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

Review 3.  DNA vaccines for prostate cancer.

Authors:  Christopher D Zahm; Viswa Teja Colluru; Douglas G McNeel
Journal:  Pharmacol Ther       Date:  2017-02-07       Impact factor: 12.310

4.  A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.

Authors:  Joshua M Lang; Marianne Wallace; Jordan T Becker; Jens C Eickhoff; Bjoern Buehring; Neil Binkley; Mary Jane Staab; George Wilding; Glenn Liu; Miroslav Malkovsky; Douglas G McNeel
Journal:  Clin Genitourin Cancer       Date:  2013-07-05       Impact factor: 2.872

Review 5.  Immunotherapy for prostate cancer: an emerging treatment modality.

Authors:  Charles G Drake
Journal:  Urol Clin North Am       Date:  2010-02       Impact factor: 2.241

6.  Oncolytic virus-initiated protective immunity against prostate cancer.

Authors:  Shashi A Gujar; D A Pan; Paola Marcato; Katy A Garant; Patrick W K Lee
Journal:  Mol Ther       Date:  2011-01-18       Impact factor: 11.454

7.  Characterization of Immune-Based Molecular Subtypes and Prognostic Model in Prostate Adenocarcinoma.

Authors:  Li Guo; Yihao Kang; Daoliang Xia; Yujie Ren; Xueni Yang; Yangyang Xiang; Lihua Tang; Dekang Ren; Jiafeng Yu; Jun Wang; Tingming Liang
Journal:  Genes (Basel)       Date:  2022-06-18       Impact factor: 4.141

8.  Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer.

Authors:  Rebecca S Bullard; Willietta Gibson; Sudeep K Bose; Jamila K Belgrave; Andre C Eaddy; Corey J Wright; Debra J Hazen-Martin; Janice M Lage; Thomas E Keane; Tomas A Ganz; Carlton D Donald
Journal:  Mol Immunol       Date:  2007-09-14       Impact factor: 4.407

9.  Immunotherapy and immune evasion in prostate cancer.

Authors:  Archana Thakur; Ulka Vaishampayan; Lawrence G Lum
Journal:  Cancers (Basel)       Date:  2013-05-24       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.